Search

Author/Creator BOMPAS, Emmanuelle

1. Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial. Issue 4 (April 2021)

Authors:
Guigay, Joël; Aupérin, Anne; Fayette, Jérôme; Saada-Bouzid, Esma; Lafond, Cédrik; Taberna, Miren; Geoffrois, Lionnel; Martin, Laurent; Capitain, Olivier; Cupissol, Didier; Castanie, Hélène; Vansteene, Damien; Schafhausen, Philippe; Johnson, Alison; Even, Caroline; Sire, Christian; Duplomb, Sophie...
Journal:
Lancet oncology
Issue:
Volume 22:Issue 4(2021)
Page Start:
463
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trial. Issue 8 (August 2022)

Authors:
Pautier, Patricia; Italiano, Antoine; Piperno-Neumann, Sophie; Chevreau, Christine; Penel, Nicolas; Firmin, Nelly; Boudou-Rouquette, Pascaline; Bertucci, François; Balleyguier, Corinne; Lebrun-Ly, Valérie; Ray-Coquard, Isabelle; Kalbacher, Elsa; Bardet, Aurélie; Bompas, Emmanuelle; Collard, Olivi...
Journal:
Lancet oncology
Issue:
Volume 23:Issue 8(2022)
Page Start:
1044
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search